1-(6-Fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol;hydron;chloride
(JWEXHQAEWHKGCW-UHFFFAOYSA-N)
Structure
- SMILES
- OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O.Cl
- Molecular Formula:
- C22H26ClF2NO4
- Molecular Weight:
- 441.896
- Log P:
- 3.5565
- Hydrogen Bond Acceptor:
- 5
- Hydrogen Bond Donor:
- 4
- TPSA:
- 70.95
- CAS Number(s):
- 152520-56-4; 169293-50-9
Synonym(s)
1.
1-(6-Fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol;hydron;chloride
2.
Bis[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]azanium;chloride
3.
Nebivolol HCl
External Link(s)
| PubChem Compound | 91827721 45371156 9933004 |
| CHEMBL | CHEMBL1201731 |
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Bradycardia | FAERS: 3 | US FAERS | |
| 2 | Cytolytic hepatitis | FAERS: 2 | US FAERS | |
| 3 | Drug exposure during pregnancy | FAERS: 2 | US FAERS | |
| 4 | Fatigue | FAERS: 2 | US FAERS | |
| 5 | Hepatitis | FAERS: 2 | US FAERS | |
| 6 | Lupus-like syndrome | FAERS: 2 | US FAERS | |
| 7 | Angioedema | FAERS: 1 | US FAERS | |
| 8 | Anti-thyroid antibody positive | FAERS: 1 | US FAERS | |
| 9 | Anxiety | FAERS: 1 | US FAERS | |
| 10 | Arthralgia | FAERS: 1 | US FAERS | |
| 11 | Asthenia | FAERS: 1 | US FAERS | |
| 12 | Blood albumin decreased | FAERS: 1 | US FAERS | |
| 13 | Cerebral disorder | FAERS: 1 | US FAERS | |
| 14 | Complement factor C4 decreased | FAERS: 1 | US FAERS | |
| 15 | Diabetes mellitus inadequate control | FAERS: 1 | US FAERS | |
| 16 | Dizziness | FAERS: 1 | US FAERS | |
| 17 | Flatulence | FAERS: 1 | US FAERS | |
| 18 | Hypotension | FAERS: 1 | US FAERS | |
| 19 | Lymphocyte count decreased | FAERS: 1 | US FAERS | |
| 20 | Myalgia | FAERS: 1 | US FAERS | |
| 21 | Nausea | FAERS: 1 | US FAERS | |
| 22 | Nipple pain | FAERS: 1 | US FAERS | |
| 23 | Overdose | FAERS: 1 | US FAERS | |
| 24 | Palpitations | FAERS: 1 | US FAERS | |
| 25 | Performance status decreased | FAERS: 1 | US FAERS | |
| 26 | Pregnancy | FAERS: 1 | US FAERS | |
| 27 | Retinal Detachment | FAERS: 1 | US FAERS | |
| 28 | Sicca Syndrome | FAERS: 1 | US FAERS | |
| 29 | Sinoatrial Block | FAERS: 1 | US FAERS | |
| 30 | Sinus bradycardia | FAERS: 1 | US FAERS | |
| 31 | Suicide attempt | FAERS: 1 | US FAERS | |
| 32 | Tenosynovitis | FAERS: 1 | US FAERS | |
| 33 | Transferrin decreased | FAERS: 1 | US FAERS | |
| 34 | Visual Impairment | FAERS: 1 | US FAERS | |
| 35 | Wheelchair user | FAERS: 1 | US FAERS |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.